#15: TheMachine: BioAlliance Pharma Announces a 786% Increase in Revenues for the Fourth Quarter of 2007
Regulatory News:
BioAlliance Pharma SA (Paris:BIO) has... |
February 5, 2008
06:10:58 AM |
#14: TheMachine: BioAlliance Pharma Publishes Its 2008 Financial Calendar and Announces the Opening of Its European Corporate Headquarters
Regulatory News:
BioAlliance Pharma SA (PARIS:BIO)... |
February 5, 2008
06:10:34 AM |
#13: NewsBot: BIO News Trafalgar Asset UK Regulatory Announcement: Rule 8.3 - Biotrace Int'l CFD
LONDON--(BUSINESS WIRE)--
FORM 8.3DEALINGS BY PERSONS WITH INTERESTS IN... |
November 1, 2006
07:44:00 AM |
#12: NewsBot: BIO News BioAlliance Pharma Receives Marketing Authorisation for Its First Product, Loramyc(R)
PARIS--(BUSINESS WIRE)--BioAlliance Pharma SA (Paris:BIO), an emerging specialty... |
October 13, 2006
09:11:00 AM |
#10: NewsBot: BIO News BioAlliance Pharma Strengthens International Capabilities in Key Legal, IP and Regulatory Departments
PARIS--(BUSINESS WIRE)--July 17, 2006--BioAlliance Pharma SA(PARIS: BIO), an... |
July 17, 2006
02:34:00 AM |
#11: NewsBot: BIO News BioAlliance Pharma renforce ses compétences internationales sur trois métiers clefs pour son expansion : le juridique, la propriété industrielle et les affaires réglementaires
PARIS--(BUSINESS WIRE)--17 juillet 2006--BioAlliance Pharma (PARIS: BIO),... |
July 17, 2006
02:34:00 AM |
#9: NewsBot: BIO News BioAlliance Pharma annonce les résultats préliminaires de l'essai clinique de Phase I/II de doxorubicine Transdrug® pour le traitement du cancer primitif du foie
PARIS--(BUSINESS WIRE)--30 juin 2006-- Cette annonce intervient à... |
June 30, 2006
07:10:00 AM |
#8: NewsBot: BIO News BioAlliance Pharma Announces Preliminary Results of its Doxorubicin Transdrug(R) Phase I/II Clinical Trial for Primary Liver Cancer
PARIS--(BUSINESS WIRE)--June 30, 2006-- BioAlliance Pharma Presents Results... |
June 30, 2006
07:07:00 AM |
#7: NewsBot: BIO News BioAlliance Pharma renforce son équipe opérationnelle en vue du lancement du Loramyc®
PARIS--(BUSINESS WIRE)--26 juin 2006--BioAlliance Pharma (Paris:BIO), société... |
June 26, 2006
02:57:00 AM |
#6: NewsBot: BIO News BioAlliance Pharma Strengthens Operational Management Ahead of Loramyc(R) Launch
PARIS--(BUSINESS WIRE)--June 26, 2006--BioAlliance Pharma SA (Paris:BIO), an... |
June 26, 2006
02:37:00 AM |
#5: NewsBot: BIO News BioAlliance Pharma participe à la première conférence londonienne de Piper Jaffray consacrée à la santé
PARIS--(BUSINESS WIRE)--21 juin 2006-- Dominique Costantini, Présidente du... |
June 21, 2006
07:16:00 AM |
#4: NewsBot: BIO News BioAlliance Pharma Presents at First Ever Piper Jaffray London Healthcare Conference; CEO Dominique Costantini Delivers Presentation on Forthcoming Events at BioAlliance
PARIS--(BUSINESS WIRE)--June 21, 2006--BioAlliance Pharma SA (Paris:BIO), an... |
June 21, 2006
07:15:00 AM |
#3: NewsBot: BIO News HARTWIG II UK Regulatory Announcement: Rule 8.3 - Biofocus - Replacement
LONDON--(BUSINESS WIRE)--
The issuer advises that the following replaces the... |
October 11, 2005
09:53:00 PM |
#2: NewsBot: BIO News Hartwig II UK Regulatory Announcement: Rule 8.3 - Biofocus
LONDON--(BUSINESS WIRE)--
-0
FORM 8.3
DEALINGS BY PERSONS WHO OWN OR CONTROL 1%... |
October 11, 2005
05:09:00 AM |
#1: NewsBot: BIO News Hartwig II UK Regulatory Announcement: Rule 8.3 - BIOFOCUS
LONDON--(BUSINESS WIRE)--
FORM 8.3
DEALINGS BY PERSONS WHO OWN OR CONTROL 1%... |
October 10, 2005
10:31:00 PM |
| 
| 
| 
| 
| 
| 
